Temporal Interference for Essential Tremor
Launched by LIANKUN_REN · Jun 3, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new treatment called temporal interference (TI) for people with essential tremor, a condition that causes shaking in the hands and arms. The study will involve adults aged 30 to 70 who experience tremors in one or both arms. To participate, individuals must not have any serious mental health issues, must be able to give informed consent, and should not have other neurological conditions or certain health problems that could interfere with the study.
Participants in this trial can expect to receive the TI treatment and will be monitored for its effectiveness in reducing their tremors. It’s important to note that those with moderate to severe cognitive impairment, certain orthopedic issues, or who are on specific medications will not be eligible to join. This study is still in the planning stages and has not started recruiting participants yet, so stay tuned for more updates if you think this trial might be right for you or someone you know.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged 30-70 years old, regardless of gender. Action tremor and postural tremor in both upper limbs, or action tremor and postural tremor in one limb;
- • No history of mental diseases;
- • Informed consent signed.
- Exclusion Criteria:
- • Presence of other neurological diseases affecting the study (such as epilepsy);
- • Patients with moderate to severe cognitive impairment (Montreal Cognitive Assessment ≤ 18 points);
- • Orthopedic diseases that may affect motor symptoms;
- • Patients taking antipsychotic or antidepressant medications;
- • Presence of metal implants in the body (such as brain pacemakers or cardiac pacemakers);
- • History of electroconvulsive therapy;
- • Presence of cardiovascular risk factors, etc.
About Liankun Ren
Liankun Ren is a dedicated clinical trial sponsor specializing in advancing medical research and innovation. With a strong commitment to improving patient outcomes, Liankun Ren collaborates with healthcare professionals and institutions to design and implement rigorous clinical studies. The organization focuses on a range of therapeutic areas, employing state-of-the-art methodologies to ensure the highest standards of safety and efficacy in its trials. Through its strategic partnerships and adherence to regulatory guidelines, Liankun Ren aims to contribute significantly to the development of new therapies and enhance the overall landscape of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Liankun Ren, MD
Principal Investigator
Xuanwu Hospital, Beijing
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported